

해외 바이오의약품 임상 현황 ('23년 12월 4주)

한국바이오의약품협회, 2024.01.02.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov
- 모니터링 기간: 2023.12.25.~2023.12.31.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 29건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06026657	Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer	Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Gemcitabine Procedure: Magnetic Resonance Imaging Biological: Naxitamab Biological: Universal Donor Expanded TGF-beta-imprinted NK Cells	Margaret Gatti-Mays Ohio State University Comprehensive Cancer Center	Phase 1 Phase 2	
NCT05756166	Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer	Procedure: Biopsy Procedure: Biospecimen Collection Drug: Celecoxib Procedure: Computed Tomography Biological: Interferon Alpha-2 Procedure: Magnetic Resonance Imaging Biological: Pembrolizumab Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 1 Phase 2	
NCT06178588	Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Procedure: Positron Emission Tomography Biological: Sacituzumab Govitecan	University of Kansas Medical Center National Cancer Institute (NCI)	Phase 2	
NCT06140407	Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer	Drug: Cisplatin Drug: Carboplatin Drug: Etoposide Biological: Pembrolizumab Procedure: Computed Tomography Procedure: Positron Emission Tomography Procedure: Magnetic Resonance Imaging Procedure: Biospecimen Collection Radiation: Radiation Therapy	Vanderbilt-Ingram Cancer Center Merck Sharp & Dohme LLC	Phase 2	
NCT06096779	A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis	Drug: Atezolizumab Drug: Bevacizumab	Genentech, Inc.	Phase 2	
NCT06048250	Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma	Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration Procedure: Computed Tomography Biological: Mezigdomide Procedure: Positron Emission Tomography	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	
NCT06046248	Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease	Drug: Belumosudil Drug: Rituximab	Northside Hospital, Inc. Sanofi	Phase 2	
NCT05981209	Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies	Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration Procedure: Bone Marrow Biopsy Procedure: Computed Tomography Drug: Dexamethasone Procedure: Echocardiography Biological: Elotuzumab Procedure: Magnetic Resonance Imaging Biological: Mezigdomide Procedure: X-Ray Imaging	Abdullah Khan Ohio State University Comprehensive Cancer Center	Phase 1	

해외 바이오의약품 임상 현황 ('23년 12월 4주)

한국바이오의약품협회, 2024.01.02.

○ 미국 29건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05910801	Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration Procedure: Bone Marrow Biopsy Procedure: Computed Tomography Drug: Lenalidomide Procedure: Lumbar Puncture Procedure: Magnetic Resonance Imaging Procedure: Positron Emission Tomography Biological: Tafasitamab Drug: Venetoclax	Academic and Community Cancer Research United National Cancer Institute (NCI)	Phase 2	
NCT05901545	Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer	Biological: Panitumumab Other: Indium In 111 Panitumumab Procedure: Single Photon Emission Computed Tomography Procedure: Computed Tomography Procedure: Surgical Procedure Other: Imaging agent Procedure: Intraoperative Imaging Procedure: Near Infrared Imaging Procedure: Electrocardiography Procedure: Biospecimen Collection	Vanderbilt-Ingram Cancer Center American Cancer Society, Inc.	Phase 1	
NCT05805371	PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer	Biological: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Bone Scan Procedure: Computed Tomography Radiation: External Beam Radiation Therapy Procedure: Leukapheresis Procedure: Lymphodepletion Therapy	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	
NCT05672251	Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Biological: Loncastuximab Tesirine Biological: Mosunetuzumab Procedure: Positron Emission Tomography	City of Hope Medical Center National Cancer Institute (NCI)	Phase 2	
NCT05672147	CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia	Biological: Anti-CD33 CAR T-cells Procedure: Lymphodepletion Therapy	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	
NCT04093323	Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma	Biological: Alpha-type-1 Polarized Dendritic Cells Drug: Celecoxib Drug: PD-1 Ligand Inhibitor Drug: PD1 Inhibitor Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 2	
NCT06164275	Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Dacarbazine Drug: Doxorubicin Procedure: Echocardiography Procedure: Multigated Acquisition Scan Biological: Pembrolizumab Procedure: Positron Emission Tomography Drug: Vinblastine	Northwestern University National Cancer Institute (NCI)	Phase 2	
NCT06137118	AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia	Drug: AZD0486	AstraZeneca	Phase 1 Phase 2	

해외 바이오의약품 임상 현황 ('23년 12월 4주)

한국바이오의약품협회, 2024.01.02.

○ 미국 29건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06059391	CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Procedure: Biospecimen Collection Drug: Granulocyte Colony-Stimulating Factor Drug: Hematopoietic Cell Transplantation Conditioning Regimen Biological: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine Procedure: Pheresis Drug: Placebo Administration Drug: Stem Cell Mobilization Therapy	City of Hope Medical Center National Cancer Institute (NCI)	Phase 2	
NCT05606757	A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique	Drug: BOTOX Dose A Drug: Placebo for BOTOX Drug: BOTOX Dose B Drug: BOTOX Dose C	AbbVie	Phase 2	
NCT05231122	Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	Biological: Anti-CD40 Agonist Monoclonal Antibody CDX-1140 Biological: Bevacizumab Biological: Pembrolizumab Other: Quality-of-Life Assessment Other: Questionnaire Administration	Roswell Park Cancer Institute National Cancer Institute (NCI) Merck Sharp & Dohme LLC Celldex Therapeutics	Phase 2	
NCT06121843	A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma	Drug: BMS-986393 Drug: Alnuctamab Drug: Mezigdomide Drug: Iberdomide	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	Phase 1	
NCT05911321	Isa-Pom-Dex in Elderly/Frail Subjects With RRMM	Drug: Isatuximab Drug: Pomalidomide Drug: Dexamethasone	UNC Lineberger Comprehensive Cancer Center Genzyme, a Sanofi Company	Phase 2	
NCT05826015	AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer	Drug: Paclitaxel Drug: Batiraxcept	Washington University School of Medicine National Cancer Institute (NCI) Aravive, Inc.	Phase 1	
NCT05643638	A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD	Biological: CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs) Biological: Placebo Drug: Corticosteroids	Cynata Therapeutics Limited	Phase 2	
NCT06147037	A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours	Drug: FPI-2053 Drug: [111In]-FPI-2107 Drug: [225Ac]-FPI-2068	Fusion Pharmaceuticals Inc. AstraZeneca	Phase 1	
NCT06179511	Study of AZD9829 in CD123+ Hematological Malignancies	Drug: AZD9829	AstraZeneca	Phase 1 Phase 2	
NCT06008093	A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients	Drug: Durvalumab Drug: Tremelimumab Drug: Pemetrexed Drug: Pembrolizumab Drug: Carboplatin Drug: Cisplatin	AstraZeneca	Phase 3	
NCT06174987	A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)	Drug: T-DXd	Daiichi Sankyo, Inc. AstraZeneca	Phase 3	

해외 바이오의약품 임상 현황 ('23년 12월 4주)

한국바이오의약품협회, 2024.01.02.

○ 미국 29건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05925530	Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-III B NSCLC (MDT-BRIDGE)	Drug: Durvalumab	AstraZeneca	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05925530
NCT05280314	Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab in Patients With Resectable Tumors	Drug: IO102-IO103 Drug: Pembrolizumab	IO Biotech Theradex Almac Merck Sharp & Dohme LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05280314

○ 영국 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06174987	A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)	Drug: T-DXd	Daiichi Sankyo, Inc. AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06174987

○ 프랑스 4건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06067061	"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer	Combination Product: Atezolizumab + RP1	Institut Curie Replimune Inc. Roche Pharma AG	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06067061
NCT06137118	AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia	Drug: AZD0486	AstraZeneca	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06137118
NCT05925530	Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-III B NSCLC (MDT-BRIDGE)	Drug: Durvalumab	AstraZeneca	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05925530
NCT06174987	A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)	Drug: T-DXd	Daiichi Sankyo, Inc. AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06174987

○ 독일 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06137118	AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia	Drug: AZD0486	AstraZeneca	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06137118
NCT05925530	Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-III B NSCLC (MDT-BRIDGE)	Drug: Durvalumab	AstraZeneca	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05925530
NCT06179511	Study of AZD9829 in CD123+ Hematological Malignancies	Drug: AZD9829	AstraZeneca	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06179511

해외 바이오의약품 임상 현황 ('23년 12월 4주)

한국바이오의약품협회, 2024.01.02.

○ 중국 14건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06180174	Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma	Biological: MC-1-50	Chongqing Precision Biotech Co., Ltd Peking University Cancer Hospital & Institute	Phase 1	
NCT06179524	CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL	Biological: CAR-T-19 cell injection	Beijing Yongtai Ruike Biotechnology Company Ltd	Phase 2	
NCT06167915	Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine (CHO Cell) LYB002V14 in Booster Vaccination	Biological: 30µg dose of LYB002V14 Biological: 60µg dose of LYB002V14 Biological: placebo	Guangzhou Patronus Biotech Co., Ltd. Yantai Patronus Biotech Co., Ltd.	Phase 1	
NCT06081907	The Efficacy and Safety of IBI363 in Solid Tumors.	Drug: IBI363	Hunan Province Tumor Hospital Xiangya Hospital of Central South University	Phase 1	
NCT06080256	Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis (EAST-aICAS)	Drug: Alirocumab Drug: Atorvastatin	The First Affiliated Hospital with Nanjing Medical University	Phase 3	
NCT06014190	HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer	Drug: HS-20089	Hansoh BioMedical R&D Company	Phase 2	
NCT05338580	Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors	Drug: TJ271 Injection in Combination with Pembrolizumab	I-Mab Biopharma Co. Ltd.	Phase 2	
NCT05296603	Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer	Drug: IBI-322 Plus Lenvatinib	Hunan Province Tumor Hospital	Phase 2	
NCT05296278	Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC	Drug: IBI-323 combined with bevacizumab plus Platinum	Hunan Province Tumor Hospital	Phase 2	
NCT04947033	A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors	Drug: TJ210001 Injection	I-Mab Biopharma Co. Ltd.	Phase 1	
NCT06167486	SG2918 For Advanced Malignant Tumors	Drug: SG2918	Hangzhou Sumgen Biotech Co., Ltd.	Phase 1	
NCT06173037	RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer	Drug: RC88	RemeGen Co., Ltd.	Phase 2	
NCT06143735	A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Receiving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors	Drug: Efbemalenograstim alfa	Tianjin Medical University Cancer Institute and Hospital Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 2	
NCT06174987	A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)	Drug: T-DXd	Daiichi Sankyo, Inc. AstraZeneca	Phase 3	

해외 바이오의약품 임상 현황 ('23년 12월 4주)

한국바이오의약품협회, 2024.01.02.

○ 일본 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06179511	Study of AZD9829 in CD123+ Hematological Malignancies	Drug: AZD9829	AstraZeneca	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06179511
NCT06174987	A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)	Drug: T-DXd	Daiichi Sankyo, Inc. AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06174987